• Description
    • Almost there.

      Please provide a bit of info so we know which materials are helpful to you. You will only need to enter this info once.

      We respect your privacy & do not sell data.

  • Contact Info
  • This field is for validation purposes and should be left unchanged.

Mirtazapine for Methamphetamine Use Disorder and HIV Prevention


Click here for a recording of the webinar

The epidemic of methamphetamine use is increasingly recognized as a
driver of HIV risk behavior and transmission in the United States. More tools are needed to treat methamphetamine use disorder and to mitigate associated health risks.

In this webinar, Dr. Phillip O. Coffin will present the findings of his recently published randomized control trial evaluating the use of the medication mirtazapine to treat methamphetamine use disorder and assist with HIV risk reduction among MSM. Dr. Coffin, Emalie Huriaux from the Washington Department of Health, and Dr. Jeff Allgaier from Ideal Option Addiction Medicine Practice will discuss how Health Departments and Community Based Organizations may incorporate finding of this study into their HIV prevention strategy for people with substance use disorders.

Upon completion of this webinar, participants will be able to:
1) List two major threats to the health of people who use methamphetamine.
2) Identify the strength of evidence for methamphetamine use in contributing to HIV transmission.
3) Summarize recent evidence for the use of mirtazapine in the treatment of methamphetamine use disorder and HIV risk reduction.